As specific diagnostic entities with recurrent genetic abnormalities, B-ALL/lymphoblastic lymphoma and AML with KMT2A rearrangements are categories included in the latest classification of the World Health Organization (5th WHO) and the International Consensus Classification (2022 ICC) [18,19,20]. This evidence concerns the gene KMT2A and acute myeloid leukemia.